Press release
Releases New Report on the CEA Antibodies Market
The elevated levels of carcinoembryonic antigens results in different types of cancers and other conditions such as cholecystitis, lung infection, heavy smoking, inflammatory bowel diseases, peptic and ulcer. High level of carcinoembryonic antigens is also found in the patients who are not diagnosed with cancer. This increases the risk of developing cancer in such patients. Hematoma (blood accumulating under the skin), infection, dizziness and excessive bleeding are some of the risks associated with abnormal levels of CEA.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4682
The abnormal levels of CEA in the body can be detected by using arcitumomab, a monoclonal antibody. This is commonly utilized in identification of glycoprotein expression in tissue samples. CEA antibody acts against the CEA, and help treat patients with presence of CEA protein. Hence, this antibody in utilized extensively to treat the patients suffering from CEA associated cancers.
Several drugs (CEA antibody) are currently available in the market that are utilized to treat CEA cancer. Pan CEA and clone II-7 are some of the examples of CEA antibody drugs. Discovery of specific antigens and biomarkers propels the growth of carcinoembryonic antigen antibody market. Similarly, continuous technological advancements in the drugs will also augment the growth of carcinoembryonic antigen antibody market. Likewise, rise in geriatric population also supports the growth of carcinoembryonic antigen antibody market.
This is due to the fact that this class of population is at higher risk for developing CEA associated cancers. The World Health of Organization has estimated that by 2050, around 2 billion people belong to this population. However, lack of awareness and availability of novel technological solutions might pose a challenge to the growth of CEA antibody market.
In 2012, North America accounted for the largest share of the global carcinoembryonic antigen antibody market. This is due to the presence of large number of companies engaged in developing and manufacturing carcinoembryonic antigen antibodies. Also, increasing R&D expenditure by various players in the region will augment the growth of carcinoembryonic antigen antibody market.
Likewise, increasing government initiatives regarding the development of carcinoembryonic antigen antibody will further accentuate the growth of carcinoembryonic antigen antibody market. Europe accounted for the second largest share by revenue in 2012 of global carcinoembryonic antigen antibody market. This large market revenue is attributed to the presence of large geriatric population coupled with increasing healthcare expenditure in the region.
Asia-Pacific along with Rest of the World (RoW) contributed smallest share in the global carcinoembryonic antigen antibody market in 2012. Lack of awareness coupled with presence of few pharmaceutical companies that are engaged in developing and manufacturing carcinoembryonic antigen antibodies restrict the growth of carcinoembryonic antigen antibody market in these two regions of the globe.
Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=4682<ype=S
Some of the major players operating in the carcinoembryonic antigen antibody market include Abbott Laboratories, Siemens Healthcare, bioMerieux, Danaher Corporation (Beckman Coulter), Myriad Genetics, Epigenomics, Qiagen N.V., and Life Technologies Corporation among other significant players.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Releases New Report on the CEA Antibodies Market here
News-ID: 883479 • Views: …
More Releases from Transparency Market Research
Cloud Artificial Intelligence (AI) Solutions Market Poised for Exponential Growt …
The Global Cloud Artificial Intelligence (AI) Solutions Market (클라우드 인공지능(AI) 솔루션 시장) is set for remarkable growth, with projections indicating a leap from $38.1 billion in 2022 to an estimated $254.6 billion by 2031. This represents a robust compound annual growth rate (CAGR) of 24.1% over the forecast period of 2023 to 2031. The rapid expansion of the market reflects the transformative potential of cloud-based AI technologies across diverse industries.
Cloud-based…
Global Smart Agriculture Market Poised for Significant Growth, Expected to Excee …
The Global Smart Agriculture Market (スマート農業市場), valued at approximately US$ 10.02 billion in 2020, is set to experience robust expansion, with an anticipated compound annual growth rate (CAGR) of 13.30% from 2021 to 2031. Market analysts project that the sector will surpass US$ 39.02 billion by the end of the forecast period, driven by advancements in technology and increasing adoption of digital solutions in farming practices.
Download Sample PDF from Here-…
Real-Time Flood Monitoring & Warning System Market Expected to Grow at 6.2% CAGR …
The Global Real-Time Flood Monitoring and Warning System Market (실시간 홍수 모니터링 및 경고 시스템 시장), valued at over USD 184.1 million in 2020, is set to witness substantial growth over the next decade. According to industry analysts, the market is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2031, ultimately surpassing USD 359.5 million by the end of the forecast period.
The increasing…
Global Asset and Wealth Management Market Set for Explosive Growth, Projected to …
The Global Asset and Wealth Management Market (資産および資産管理市場), valued at US$ 3.5 billion in 2021, is projected to expand at a robust CAGR of 13.0% from 2022 to 2031, reaching a market value of US$ 11.8 billion by the end of the forecast period.
The asset and wealth management industry is witnessing rapid evolution, spurred by the integration of advanced technologies, regulatory changes, and shifting investor demographics. As technology plays an…
More Releases for CEA
Carcinoembryonic Antigen (CEA) Market Size, Share | Industry Report 2026
The global Carcinoembryonic Antigen (CEA) Market was valued at $5.3 Billion in 2018 and is forecast to grow at a modest 6.1 % CAGR between 2018 and 2026, culminating in 2026 global sales of $ 9.2 Billion.
Carcinoembryonic AntigenTest is a blood test which identifies the diagnose and manage certain cancer disease like rectum and large intestine. Basically, it is used to check how well treatment is working in certain…
Carcinoembryonic Antigen (CEA) Market Investment Research Report 2017 – 2027
Carcinoembryonic antigen (CEA) is normally found in embryonic entodermal epithelium. Carcinoembryonic antigen is a group of glycoprotein present in the body fluids of the fetus and embryo and in the gastrointestinal tract. Carcinoembryonic antigen is also present in the mucosal cells of the colorectum, gastrointestinal cells, and small amounts are present in the blood. Carcinoembryonic antigen is produced by the gastrointestinal tissues during the development of fetal. CEA is not…
CEA Testing Market Progresses For Huge Profits During 2019
Carcinoembryonic antigen (CEA) is a protein usually produced in the developing fetus and disappears or is absent in adults. Abnormal amounts of this protein may lead to cancer. CEA test is performed to measure the level of proteins and check for the recurrence of colon and other cancers in patients already diagnosed with cancer. The normal accepted range of this protein is 0 micrograms to 0.25 micrograms per liter. Elevated…
CEA Testing Market Intelligence with Competitive Landscape 2019
Carcinoembryonic antigen (CEA) is a protein usually produced in the developing fetus and disappears or is absent in adults. Abnormal amounts of this protein may lead to cancer. CEA test is performed to measure the level of proteins and check for the recurrence of colon and other cancers in patients already diagnosed with cancer. The normal accepted range of this protein is 0 micrograms to 0.25 micrograms per liter. Elevated…
Carcinoembryonic Antigen (CEA) Market to hit $2.7bn by 2023
Carcinoembryonic Antigen (CEA) Market size is driven by increasing incidence rate for cancer disease especially colorectal cancer is one of the important factor contributing to the growth. Global Carcinoembryonic Antigen Market is set to register profitable growth in the near future and surpass USD 2.8 billion by 2023.
This growth is attributed to factors including consistent technology advancements, development of novel biomarkers and growing prevalence of cancer. Global Market Insights,…
CEA Antibodies Market Outlook And Research Survey To 2023
CEA stands for carcinoembryonic antigen, is a protein that is usually produced in developing fetus and disappears or is absent in adults. Production of abnormal amount of CEA protein may lead to cancer. CEA test is performed to measure the level of proteins and check for the recurrence of colon and other cancers in patients already diagnosed with cancer. The normal accepted range of this protein that is non-cancerous in…
